Morgan Stanley Maintains Y-mAbs Therapeutics(YMAB.US) With Sell Rating, Maintains Target Price $11
Analysts Offer Insights on Healthcare Companies: Y-Mabs Therapeutics (YMAB), Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (AU:RMD) and Bayer (GB:0P6S)
Y-mAbs Therapeutics Price Target Maintained With a $23.00/Share by Wedbush
Y-mAbs Therapeutics Analyst Ratings
Cantor Fitzgerald Initiates Coverage on Y-mAbs Therapeutics With Overweight Rating, $20 Price Target
Cantor Fitzgerald Initiates Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $20
CCORF Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $26
Truist Financial Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $21
A Quick Look at Today's Ratings for Y-mAbs Therapeutics(YMAB.US), With a Forecast Between $21 to $26
HC Wainwright & Co. Reiterates Buy on Y-mAbs Therapeutics, Maintains $22 Price Target
Truist Financial Sticks to Their Buy Rating for Y-Mabs Therapeutics (YMAB)
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Taysha Gene Therapies (TSHA) and Y-Mabs Therapeutics (YMAB)
Y-mAbs Therapeutics Analyst Ratings
Buy Rating on Y-mAbs Therapeutics: Robust Sales Growth and Strong Pipeline Prospects
JonesTrading Sticks to Its Buy Rating for Y-Mabs Therapeutics (YMAB)
Recommendation to Sell on Y-Mabs Therapeutics Amid Reduced Sales Forecast and Concerns Over Profitability
Y-mAbs Therapeutics Analyst Ratings
Jones Trading Initiates Coverage On Y-mAbs Therapeutics With Buy Rating, Announces Price Target of $23
Y-mAbs Therapeutics Analyst Ratings
Truist Initiates Y-mAbs Therapeutics at Buy With $21 Price Target, Calls Radioimmunotherapy Platform 'Undervalued'